Treprostinil Struktur

Treprostinil

Bezeichnung:Treprostinil

CAS-Nr81846-19-7

Englisch Name:Treprostinil

CBNumberCB7231250

SummenformelC23H34O5

Molgewicht390.51

MOL-Datei81846-19-7.mol

Treprostinil physikalisch-chemischer Eigenschaften

Schmelzpunkt	121-123°
Siedepunkt	587.1±50.0 °C(Predicted)
Dichte	1.158±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Löslichkeit	Chloroform (Slightly, Heated), Methanol (Slightly, Heated)
Aggregatzustand	Solid
pka	3.19±0.10(Predicted)
Farbe	Off-White to Beige
Optische Aktivität	[α]/D 40 to 50°, c =0.5 in methanol
InChIKey	PAJMKGZZBBTTOY-ZFORQUDYSA-N
SMILES	C(O)(=O)COC1=C2C(=CC=C1)C[C@@]1([H])[C@@]([H])(C2)C[C@@H](O)[C@@H]1CC[C@@H](O)CCCCC

Gefahreninformationscode (GHS)

Treprostinil Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Synthetic analog of Prostacyclin (P839060). Antihypertensive. Treprostinil, marketed under the trade name Remodulin is a medication used to treat pulmonary arterial hypertension (PAH).
Definition
ChEBI: Treprostinil is a carboxylic acid and a carbotricyclic compound. It has a role as a platelet aggregation inhibitor, a vasodilator agent, an antihypertensive agent, a cardiovascular drug, a vitamin K antagonist and a human blood serum metabolite.
Biologische Aktivität
Treprostinil elicits a longer half-life when compared with iloprost. It mediates inhibition of transforming growth factor-β (TGF-β) and nuclear factor-KB (NF-KB) signaling pathways. Treprostinil effectively reduces right ventricular systolic pressure and inhibits the recruitment of circulating fibrocyte.', 'Treprostinil is a stable synthetic analog of prostacyclin (prostaglandin PGI2), an IP receptor agonist used clinically for the treatment of pulmonary arterial hypertension. It is a potent vasodilator with antithrombotic, antiproliferative and anti-inflammatory properties.
Mechanism of action
Pulmonary arterial hypertension (PAH) may be characterized by low levels of endogenous prostacyclin, which is why the prostacyclin pathway should be considered a key pathway for treatment. Treprostinil is a prostacyclin mimetic designed to supplement the endogenous prostacyclin that a patient may not be producing naturally. Treprostinil mechanism of action targets 3 of the major pathologic changes that occur in PAH.
Vasoconstriction: Treprostinil directly dilates pulmonary and systemic arterial vascular beds.
Platelet aggregation: Treprostinil inhibits platelet aggregation.
Smooth muscle proliferation: Treprostinil inhibits smooth muscle cell proliferation.
Pharmakokinetik
Treprostinil is rapidly absorbed from the subcutaneous site of infusion, with an almost 100% bioavailability and a mean half-life of 85 minutes (34 minutes for the IV infusion). The IV solution must be diluted with normal saline or sterile water before starting the infusion. Unlike epoprostenol, treprostinil is stable at room temperature for up to 5 years, with vasodilation action lasting from 4 to 6 hours, compared with the short, 2- to 3-minute action for epoprostenol. Because of its long life in the body, it can be administered under the skin with a microinfusion subcutaneous infusion pump rather than into the bloodstream and, thus, without hospitalization, as contrasted with the central IV infusion of epoprostenol.
Clinical Use
Treprostinil is a synthetic, stable form of prostacyclin for the treatment for advanced pulmonary hypertension with NYHA class III or IV symptoms as well as for late-stage peripheral vascular disease (PVD). Its sodium salt injectable form is administered either as a continuous subcutaneous infusion directly into the skin or, if the subcutaneous infusion is not tolerated, as a continuous IV infusion without an implanted catheter.
Nebenwirkungen
Side effects include jaw pain, headaches, nausea, diarrhea, flushing, and localized pain at the delivery site under the skin. This pain has been reported as slight to severe irritation. Patients using the drug seem to ex-perience improvement in their condition, including decreased fatigue, decreased shortness of breath, and decreased pulmonary artery pressures, as well as overall improvement in quality of life.
Synthese
A 250-mL, round-bottom flask with a magnetic stirrer was charged with treprostinil diethanolamine salt (4 g) and water (40 mL). The mixture was stirred to obtain a clear solution. Ethyl acetate (100 mL) was added to the clear solution. While stirring, 3M HCl (3.2 mL) was added slowly until pH=1 was attained. The mixture was stirred for 10 minutes, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with water (2×100 mL) and brine (1×50 mL) and dried over anhydrous Na2SO4. The ethyl acetate solution of treprostinil was filtered, and the filtrate was concentrated under a vacuum at 50° C. to give an off-white solid. The crude treprostinil was recrystallized from 50% ethanol in water (70 mL). The pure treprostinil was collected in a Buchner funnel by filtration, and the cake was washed with a cold 20% ethanolic solution in water. The cake of treprostinil was air-dried overnight and further dried in a vacuum oven at 50° C under high vacuum to afford 2.9 g of treprostinil (Yield 91.4%).
Lager
Store at -20°C

Treprostinil Upstream-Materialien And Downstream Produkte

Treprostinil Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

81846-19-7, Treprostinil Verwandte Suche:

Send Inquriy